Article

Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells.

INRS-Institut Armand-Frappier, 531 boulevard des Prairies, Laval, QC, Canada.
European Journal of Pharmacology (Impact Factor: 2.68). 09/2008; 593(1-3):92-8. DOI: 10.1016/j.ejphar.2008.06.085
Source: PubMed

ABSTRACT Certain lactone-containing secondary plant metabolites display potent biological effects, including anti-tumor activities. This is of particular interest as these compounds appear effective against hormone-dependent cancers, such as those of breast and prostate, of which the incidence is on the rise. The mechanisms of anti-tumor action of these compounds are largely unknown. Thirteen synthetic lactone derivatives were evaluated for effects on aromatase activity and mRNA expression in H295R human adrenocortical carcinoma cells. Aromatase (CYP19) is a key enzyme in the synthesis of estrogens from androgens. Over-expression has been associated with increased risk of developing estrogen-dependent mammary tumors, and aromatase inhibitors are effective in their treatment. The androgen receptor is implicated in mediating hormone-dependent prostate tumor growth, and androgen antagonists are effective in the treatment of these cancers. Thus the (anti)androgenic effects of the lactones were also assessed in LNCaP human prostate cancer cells transfected with human androgen receptor and an androgen receptor-responsive luciferase reporter gene. Cells were exposed to lactones (0.1-100 microM) dissolved in dimethyl sulfoxide (0.1% in medium) for 24 h prior to measurement of aromatase activity using a tritiated water-release assay. Three (competitive) inhibitors of aromatase activity were identified (potencies in decreasing order): 3-(3,4-dimethoxy-phenyl)-4-(4-methoxy-phenyl)-5H-furan-2-one (CRI-7; IC(50)=1 microM; K(i)=1.0 microM), 3,4-bis-(3,4-dimethoxy-phenyl)-5H-furan-2-one (CRI-8; IC(50)=2 microM; K(i)=1.2 microM) and 3-(3,4-dimethoxy-phenyl)-4-(3,4,5-trimethoxy-phenyl)-5H-furan-2-one (CRI-9; IC(50)=3 microM; K(i)=6.8 microM). Several concentration-dependent inducers of aromatase (>2fold) were also identified (CRI-1, CRI-4 or Vioxx, CRI-11 and CRI-13). These lactones also induced pII promoter-specific CYP19 transcripts. In transfected LNCaP cells, the three aromatase inhibitors CRI-7, 8 and 9 demonstrated concentration-dependent anti-androgenicity above 0.1 microM in the presence of either 0.1 nM of dihydrotestosterone or the synthetic androgen R1881. The other lactones showed no consistent pro- or anti-androgenic effects in these LNCaP cells. Lactone moiety-containing molecules may form the structural basis for the development of potent drugs effective against hormone-dependent cancers.

0 Followers
 · 
141 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The mainstay targets for hormonal prostate cancer (PCa) therapies are based on negating androgen action. Recent epidemiologic and experimental data have pinpointed the key roles of estrogens in PCa development and progression. Racial and geographic differences, as well as age-associated changes, in estrogen synthesis and metabolism contribute significantly to the etiology. This article summarizes how different estrogens/antiestrogens/estrogen mimics contribute to prostate carcinogenesis, the roles of the different mediators of estrogen in the process, and the potentials of new estrogenic/antiestrogenic compounds for prevention and treatment of PCa.
    Endocrinology and metabolism clinics of North America 09/2011; 40(3):591-614, ix. DOI:10.1016/j.ecl.2011.05.002 · 2.86 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aromatic substituents migrate in a novel oxidative cyclization mediated by iodine(III) reagents. 4-Arylbut-3-enoic acids are cyclized and rearranged to 4-arylfuran-2(5H)-ones by hypervalent iodine compounds in good to excellent yields under mild reaction conditions. Other ring sizes are also accessible. The mechanism of the reaction is described in detail, and calculations highlight the cationic nature of the intermediates in the rearrangement. The fast access to heavily substituted furanones is used for the synthesis of biologically active derivatives.
    ChemistryOpen 12/2012; 1(6):245-50. DOI:10.1002/open.201200037 · 2.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We sought to evaluate placental growth factor (PlGF) and soluble Fms-like tyrosine kinase 1 (sFlt-1) as clinical biomarkers in chronic heart failure (HF). Vascular remodeling is a crucial compensatory mechanism in chronic HF. The angiogenic ligand PlGF and its target receptor fms-like tyrosine kinase 1 modulate vascular growth and function, but their relevance in human HF is undefined. We measured plasma PlGF and sFlt-1 in 1,403 patients from the Penn Heart Failure Study, a multicenter cohort of chronic systolic HF. Subjects were followed for death, cardiac transplantation, or ventricular assist device placement over a median follow-up of 2 years. The sFlt-1 was independently associated with measures of HF severity, including New York Heart Association functional class (p < 0.01) and B-type natriuretic peptide (p < 0.01). Patients in the 4th quartile of sFlt-1 (>379 pg/ml) had a 6.17-fold increased risk of adverse outcomes (p < 0.01). This association was robust, even after adjustment for the Seattle Failure Model (hazard ratio: 2.54, 95% confidence interval [CI]: 1.76 to 2.27, p < 0.01) and clinical confounders including HF etiology (hazard ratio: 1.67, 95% CI: 1.06 to 2.63, p = 0.03). Combined assessment of sFlt-1 and B-type natriuretic peptide exhibited high predictive accuracy at 1 year (area under the receiver-operator characteristic curve: 0.791, 95% CI: 0.752 to 0.831) that was greater than either marker alone (p < 0.01 and p = 0.03, respectively). In contrast, PlGF was not an independent marker of disease severity or outcomes. Our findings support a role for sFlt-1 in the biology of human HF. With additional study, circulating sFlt-1 might emerge as a clinically useful biomarker to assess the influence of vascular remodeling on clinical outcomes.
    Journal of the American College of Cardiology 07/2011; 58(4):386-94. DOI:10.1016/j.jacc.2011.03.032 · 15.34 Impact Factor

Full-text

Download
88 Downloads
Available from
May 15, 2014